TY - JOUR
T1 - Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment
AU - Sevilla, Julián
AU - Schiavello, Elisabetta
AU - Madero, Luis
AU - Pardeo, Manuela
AU - Guggiari, Elena
AU - Baragaño, Marta
AU - Luksch, Roberto
AU - Massimino, Maura
PY - 2012/3
Y1 - 2012/3
N2 - Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. Experience in children, however, is extremely limited. We describe the experience of the use of this drug in 8 children under a compassionate-use program in 3 Italian and 2 Spanish centers. Plerixafor was generally well tolerated; only 2 of 8 children reported adverse effects, and these were mild in intensity. Peripheral blood progenitor cell priming was improved with plerixafor in 6 of 8 patients. In the remaining 2 patients, the target CD34 cell count was below the target of 2×10 cells/kg, although in these patients cell counts before collection were good enough for leukapheresis. Plerixafor, therefore seems to be safe and effective for peripheral blood progenitor cell mobilization in children. Adverse events were comparable with those described with filgrastim alone.
AB - Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. Experience in children, however, is extremely limited. We describe the experience of the use of this drug in 8 children under a compassionate-use program in 3 Italian and 2 Spanish centers. Plerixafor was generally well tolerated; only 2 of 8 children reported adverse effects, and these were mild in intensity. Peripheral blood progenitor cell priming was improved with plerixafor in 6 of 8 patients. In the remaining 2 patients, the target CD34 cell count was below the target of 2×10 cells/kg, although in these patients cell counts before collection were good enough for leukapheresis. Plerixafor, therefore seems to be safe and effective for peripheral blood progenitor cell mobilization in children. Adverse events were comparable with those described with filgrastim alone.
KW - CD34
KW - drugs
KW - hematopoietic stem cells
KW - leukapheresis
KW - plerixafor
KW - stem cell mobilization
UR - http://www.scopus.com/inward/record.url?scp=84857924680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857924680&partnerID=8YFLogxK
U2 - 10.1097/MPH.0b013e31821c2cb8
DO - 10.1097/MPH.0b013e31821c2cb8
M3 - Article
C2 - 22009006
AN - SCOPUS:84857924680
VL - 34
SP - 146
EP - 150
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
SN - 1077-4114
IS - 2
ER -